Tiger Brokers

Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference

Reuters
Mar 03
Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will present one oral and two poster sessions at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Copenhagen, held in-person and online March 17-21, 2026, showcasing new data on enhanced brain delivery of sabirnetug, sabirnetug biomarker treatment responses, and new amyloid beta oligomer-targeting antibodies. Event-related materials: https://www.globenewswire.com/Tracker?data=vC5S76bf6EVdiMsTYm3IGywLE-0tGPxq2KsimNj7ovgoYx5h3S0-ZfArUXv_aerJ6pEcU_bmHh2ggdVJCkCGjg_HO-u9tDICYpRJA-yNRcM= and the July 2025 collaboration announcement link https://www.globenewswire.com/Tracker?data=SgDD5Hkz0NkBuEH5Rlps0Q3tR3OxNamB6mEBvyQqnLQAUui2ycGEJxqxTU7Ed8SrseuZSahxLt2HFZ6Ptc5hXh2HSIFjnLCYT-t8faXGEJbQYqhItA9o-jrl1Q_fe7tyLdOUAPtwt7hED1ZHFdXAuPIRfi-0mvM6HlKDE9O48vtcWJ3EFMPJZbgNkY1BvMMBBqPpG25D400S52ejfoVe0Sx45XMKo3QL2mCqOzGG5DA=.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030800PRIMZONEFULLFEED9664542) on March 03, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10